Stefan Kertesz, a physician and addiction expert, says overaggressive cutbacks can harm some chronic pain patients.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...